Project Grant R01AI182253
Award Date
12/20/24
Completion Date
11/30/29
Dollars Obligated
$708K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Brown University (E3FDXZ6TBHW3)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
This Project Grant award for $2,960,775.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research on mechanisms that compromise CD8 T cell responses to malaria vaccination in individuals with prior malaria exposure. The primary goal is to gain mechanistic insight into how hemozoin, a byproduct of malaria infection, disrupts antigen presentation and impairs CD8 T cell priming and...
This federal Project Grant award, totaling $1,163,599.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), funds research to enhance T and B cell responses to Plasmodium infection and vaccination using IL-15 therapy. The primary award recipient is the Hennepin Healthcare Research Institute (HHRI), a non-profit research organization in Minneapolis, MN. HHRI will utilize novel mouse models and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $479,204 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore. The 2-year award, effective from July 2024 through May 2026, will support research to identify parasite variant surface antigens associated with severe malaria in Zambian children and adults. The project aims to sequence variant surface antigen transcripts from severe malaria cases and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Harvard College President & Fellows Of, through its Harvard T.H. Chan School of Public Health Division. The $889,749 grant, awarded on May 16, 2024, will fund research to globally identify the Plasmodium falciparum invasion ligand bindome, which is a critical gap in understanding the malaria parasite's invasion process. The...
This $1,845,103 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to define the immunogenic landscape of early mosquito-stage Plasmodium falciparum parasites. The goal is to accelerate the discovery of malaria transmission-blocking vaccines. The research involves using mass spectrometry-based proteomics to comprehensively catalog surface-exposed proteins in P. falciparum...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to George Washington University to develop mRNA-LNP vaccines targeting multiple stages and species of the human malaria parasite. The funding will support research to evaluate the protective efficacy of individual and combination vaccine antigens from Plasmodium falciparum and Plasmodium vivax, the two main malaria parasite species...
This $949,200 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the mechanisms underlying severe malarial anemia. The study aims to determine whether elevated levels of the enzyme xanthine oxidase (XO) contribute to the loss of uninfected red blood cells, a major factor in malaria-induced anemia. The research will examine the effects of XO from patient plasma on the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $153,512.00 to the University of Washington to conduct research on understanding and overcoming immune evasion mechanisms of the Plasmodium parasite, which causes malaria. The research aims to characterize the memory B cell response to the circumsporozoite protein (CSP) of Plasmodium during infection and...
This Project Grant award, totaling $648,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to define the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine, as well as identify resistance-refractory therapeutics. Specifically, the research aims to: Investigate the role of candidate genes MRP1 and ARPS10 in mitigating...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to study the molecular mechanisms of malaria parasite-mosquito midgut interactions and evaluate potential transmission-blocking vaccine targets. The total funding amount is $699,814, with a performance period from November 2024 to October 2029. The primary objectives are to functionally characterize mosquito and...